Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and...
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with...
NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market...
DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
Highlights Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) DMX-652 offers...
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2...
Hyundai Bioscience: "Able to Supply Antiviral Drug in Event of Ebola or Hantavirus Spread"
SEOUL, South Korea, May 20, 2026 /PRNewswire/ -- Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks...
Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology...
First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat
STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for...
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Announcement Highlights: Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease . The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was...
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide...